Severe non-hepatic hyperammonaemic encephalopathy in an immunocompromised adolescent with enterocolitis.

Autor: Borrie AE; Medicine, Dalhousie Medical School, Halifax, Nova Scotia, Canada adrienne.borrie@dal.ca., Pike M; Medicine, Dalhousie Medical School, Halifax, Nova Scotia, Canada.; Pediatric Oncology/Hematology, IWK Health Centre, Halifax, Nova Scotia, Canada., Villeneuve S; Medicine, Dalhousie Medical School, Halifax, Nova Scotia, Canada.; Pediatric Oncology/Hematology, IWK Health Centre, Halifax, Nova Scotia, Canada., Verma N; Critical Care, Dalhousie University, Halifax, Nova Scotia, Canada.

Publikováno v: BMJ case reports [BMJ Case Rep] 2024 Jun 19; Vol. 17 (6). Date of Electronic Publication: 2024 Jun 19.

Letrozole concentration is associated with CYP2A6 variation but not with arthralgia in patients with breast cancer.

Autor: Borrie AE; Division of Clinical Pharmacology, Department of Medicine, Western University, London, ON, Canada.; Department of Physiology and Pharmacology, Western University, London, ON, Canada., Rose RV; Department of Epidemiology and Biostatistics, Western University, London, ON, Canada., Choi YH; Department of Epidemiology and Biostatistics, Western University, London, ON, Canada., Perera FE; Department of Oncology, Western University, London, ON, Canada., Read N; Department of Oncology, Western University, London, ON, Canada., Sexton T; Department of Oncology, Western University, London, ON, Canada., Lock M; Department of Oncology, Western University, London, ON, Canada., Vandenberg TA; Department of Oncology, Western University, London, ON, Canada., Hahn K; Department of Oncology, Western University, London, ON, Canada., Dinniwell R; Department of Oncology, Western University, London, ON, Canada., Younus J; Department of Oncology, Western University, London, ON, Canada., Logan D; Department of Oncology, Western University, London, ON, Canada., Potvin K; Department of Oncology, Western University, London, ON, Canada., Yaremko B; Department of Oncology, Western University, London, ON, Canada., Yu E; Department of Oncology, Western University, London, ON, Canada., Lenehan J; Department of Oncology, Western University, London, ON, Canada., Welch S; Department of Oncology, Western University, London, ON, Canada., Tyndale RF; Campbell Family Mental Health Research Institute, Centre for Addiction and Mental Health (CAMH), University of Toronto, Toronto, ON, Canada.; Department of Psychiatry, and Pharmacology and Toxicology, University of Toronto, Toronto, ON, Canada., Teft WA; Division of Clinical Pharmacology, Department of Medicine, Western University, London, ON, Canada.; Department of Physiology and Pharmacology, Western University, London, ON, Canada., Kim RB; Division of Clinical Pharmacology, Department of Medicine, Western University, London, ON, Canada. richard.kim@lhsc.on.ca.; Department of Physiology and Pharmacology, Western University, London, ON, Canada. richard.kim@lhsc.on.ca.; LHSC - University Hospital, Western University, Room B9-116, 339 Windermere Road, London, ON, N6A 5A5, Canada. richard.kim@lhsc.on.ca.

Publikováno v: Breast cancer research and treatment [Breast Cancer Res Treat] 2018 Nov; Vol. 172 (2), pp. 371-379. Date of Electronic Publication: 2018 Aug 09.

Association Between SLC16A5 Genetic Variation and Cisplatin-Induced Ototoxic Effects in Adult Patients With Testicular Cancer.

Autor: Drögemöller BI; Faculty of Pharmaceutical Sciences, University of British Columbia, Vancouver, British Columbia, Canada.; BC Children's Hospital Research Institute, Vancouver, British Columbia, Canada., Monzon JG; Tom Baker Cancer Centre, Calgary, Alberta, Canada., Bhavsar AP; Faculty of Pharmaceutical Sciences, University of British Columbia, Vancouver, British Columbia, Canada.; BC Children's Hospital Research Institute, Vancouver, British Columbia, Canada., Borrie AE; Division of Translational Therapeutics, Department of Pediatrics, Faculty of Medicine, University of British Columbia, Vancouver, British Columbia, Canada.; Pharmaceutical Outcomes Programme, BC Children's Hospital, Vancouver, British Columbia, Canada., Brooks B; Audiology and Speech Pathology Department, BC Children's Hospital, Vancouver, British Columbia, Canada., Wright GEB; BC Children's Hospital Research Institute, Vancouver, British Columbia, Canada.; Department of Medical Genetics, Centre for Molecular Medicine and Therapeutics, Faculty of Medicine, University of British Columbia, Vancouver, British Columbia, Canada., Liu G; Medical Oncology and Hematology, Department of Medicine, Princess Margaret Cancer Centre - University Health Network and University of Toronto, Toronto, Ontario, Canada., Renouf DJ; BC Cancer Agency and University of British Columbia, Vancouver, British Columbia, Canada., Kollmannsberger CK; BC Cancer Agency and University of British Columbia, Vancouver, British Columbia, Canada., Bedard PL; Princess Margaret Cancer Centre and University of Toronto, Toronto, Ontario, Canada., Aminkeng F; BC Children's Hospital Research Institute, Vancouver, British Columbia, Canada.; Department of Medical Genetics, Centre for Molecular Medicine and Therapeutics, Faculty of Medicine, University of British Columbia, Vancouver, British Columbia, Canada., Amstutz U; BC Children's Hospital Research Institute, Vancouver, British Columbia, Canada.; Division of Translational Therapeutics, Department of Pediatrics, Faculty of Medicine, University of British Columbia, Vancouver, British Columbia, Canada.; University Institute of Clinical Chemistry, Inselspital Bern University Hospital and University of Bern, Bern, Switzerland., Hildebrand CA; Pharmaceutical Outcomes Programme, BC Children's Hospital, Vancouver, British Columbia, Canada., Gunaretnam EP; BC Children's Hospital Research Institute, Vancouver, British Columbia, Canada.; Division of Translational Therapeutics, Department of Pediatrics, Faculty of Medicine, University of British Columbia, Vancouver, British Columbia, Canada., Critchley C; Neuro-Otology Unit, Vancouver General Hospital, Vancouver, British Columbia, Canada., Chen Z; Medical Oncology and Hematology, Department of Medicine, Princess Margaret Cancer Centre - University Health Network and University of Toronto, Toronto, Ontario, Canada., Brunham LR; Department of Medicine, Centre for Heart Lung Innovation, University of British Columbia, Vancouver, British Columbia, Canada.; Translational Laboratory in Genetic Medicine, Agency for Science Technology and Research (A*STAR), Singapore., Hayden MR; BC Children's Hospital Research Institute, Vancouver, British Columbia, Canada.; Department of Medical Genetics, Centre for Molecular Medicine and Therapeutics, Faculty of Medicine, University of British Columbia, Vancouver, British Columbia, Canada., Ross CJD; Faculty of Pharmaceutical Sciences, University of British Columbia, Vancouver, British Columbia, Canada.; BC Children's Hospital Research Institute, Vancouver, British Columbia, Canada.; Pharmaceutical Outcomes Programme, BC Children's Hospital, Vancouver, British Columbia, Canada., Gelmon KA; BC Cancer Agency and University of British Columbia, Vancouver, British Columbia, Canada., Carleton BC; Division of Translational Therapeutics, Department of Pediatrics, Faculty of Medicine, University of British Columbia, Vancouver, British Columbia, Canada.; Pharmaceutical Outcomes Programme, BC Children's Hospital, Vancouver, British Columbia, Canada.

Publikováno v: JAMA oncology [JAMA Oncol] 2017 Nov 01; Vol. 3 (11), pp. 1558-1562.

Absence of NR2E1 mutations in patients with aniridia.

Autor: Corso-Díaz X; Centre for Molecular Medicine and Therapeutics at the Child & Family Research Institute, University of British Columbia, Vancouver, BC, Canada., Borrie AE, Bonaguro R, Schuetz JM, Rosenberg T, Jensen H, Brooks BP, Macdonald IM, Pasutto F, Walter MA, Grønskov K, Brooks-Wilson A, Simpson EM

Publikováno v: Molecular vision [Mol Vis] 2012; Vol. 18, pp. 2770-82. Date of Electronic Publication: 2012 Nov 22.